[PDF][PDF] Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial
H Serve, U Krug, R Wagner… - Journal of Clinical …, 2013 - researchgate.net
H Serve, U Krug, R Wagner, MC Sauerland, A Heinecke, U Brunnberg, M Schaich…
Journal of Clinical Oncology, 2013•researchgate.netPurpose The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal
even with intensive chemotherapy. In this trial, we compared the antileukemic activity of
standard induction and consolidation therapy with or without the addition of the kinase
inhibitor sorafenib in elderly patients with AML.
even with intensive chemotherapy. In this trial, we compared the antileukemic activity of
standard induction and consolidation therapy with or without the addition of the kinase
inhibitor sorafenib in elderly patients with AML.
Purpose
The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the antileukemic activity of standard induction and consolidation therapy with or without the addition of the kinase inhibitor sorafenib in elderly patients with AML.
researchgate.net